Survival from salivary glands adenoid cystic carcinoma in European populations
Received 7 August 2008; received in revised form 11 October 2008; accepted 14 October 2008. published online 17 December 2008.
Summary
Adenoid cystic carcinoma (ACC) of salivary gland origin is rare. The EUROCARE data provide a good opportunity to study the survival of this uncommon cancer in a large population. A total of 2611 cases, aged 15 to 99 years, diagnosed between 1983 and 1994 with primary salivary gland ACC were analyzed. Thirty-two population based cancer registries from seventeen countries participating in EUROCARE contributed the data. Relative survival by sex, age, period of diagnosis, region, site and stage, and the adjusted relative excess risk (RER) of death were estimated. Survival since diagnosis was 94%, 78% and 65% at 1, 5 and ten years, respectively. Ten-year survival was best (69%) in patients of the youngest age group (15–54 years) and from Northern Europe (69%). In the UK was higher (65%) than in Western (62%) and Eastern (56%) Europe. ACCs in nasal cavity (RER 2.6), pharynx (RER 3.5) and larynx and bronchus (RER 3.9) had a worse prognosis compared to those of oral cavity. A strong effect of stage at diagnosis on RERs and some worsening of survival at five years over time (80% in 1983–1985, 76% in 1992–1994) were also evident. The findings of the present study, as those from clinical studies, confirm the important impact of primary site and stage at diagnosis on survival. Furthermore, we could demonstrate that survival for ACC did not improve over time and that cases from Eastern countries had a significant worse prognosis. Improvements in the disease detection in its early stage and international collaborative research should be encouraged.
† EUROCARE Working Group: Austria: W Oberaigner (Tyrol Cancer Registry); Denmark: HH Storm (Danish Cancer Society, Dept. Cancer Prevention and Documentation); Estonia: T Aareleid (Estonian Cancer Registry); Czech Republic: M Jechova, M Rousarova (IHIS and West Bohemia Cancer Registry); Finland: T Hakulinen (Finnish Cancer Registry); France: G Hédelin (Bas-Rhin Cancer Registry), I Tron, E Le Gall (Bretagne Childhood Cancer Registry), G Launoy (Calvados Digestive Cancer Registry), J Macé-Lesec’h (Calvados General Cancer Registry), J Faivre (Côte d’Or Digestive Cancer Registry), G Chaplain (Côte d’Or Gynaecologic Cancer Registry), P-M Carli (Côte d’Or Malignant Haemopathies Registry), A Danzon (Doubs Cancer Registry), B Tretarre (Hérault Cancer Registry), M Colonna (Isère Cancer Registry), B Lacour (Lorraine Childhood Cancer Registry), N Raverdy (Somme Cancer Registry), C Berger, B. Freycon (Rhône-Alpes Childhood Registry), P Grosclaude (Tarn Cancer Registry), J Estève (University of Lyon); Germany: P Kaatsch (German Childhood Cancer Registry), H Ziegler (Saarland Cancer Registry), D Hölzel, G Schubert Fritschle (Munich Cancer Registry); Iceland: L Tryggvadottir (Icelandic Cancer Registry); Italy: F Berrino (Project Leader), C Allemani, P Baili, L Ciccolallo, P Crosignani, G Gatta, A Micheli, M Sant, E Taussig,S Sowe, (Istituto Nazionale per lo Studio e la Cura dei Tumori, Lombardy Cancer Registry), S Ferretti (Ferrara Cancer Registry), E Conti (Latina Cancer Registry), M Vercelli, A Quaglia (Liguria Region Cancer Registry–DOBIG Univ. GE, IST Genova), F Pannelli (Macerata Cancer Registry, Marche Childhood Cancer Registry), M Federico, ME Artioli (Modena Cancer Registry), M Ponz De Leon, P Benatti (Modena Colorectal Cancer Registry), V De Lisi, L Servente (Parma Cancer Registry), R Zanetti, S Patriarca (Piedmont Cancer Registry), C Magnani, G Pastore (Piedmont Childhood Cancer Registry), L Gafà, R Tumino (Ragusa Cancer Registry), F Falcini (Romagna Cancer Registry), M Budroni (Sassari Cancer Registry), E Paci, E Crocetti (Tuscan Cancer Registry), P Zambon, S Guzzinati (Venetian Cancer Registry), R Capocaccia, E Carrani, R De Angelis, P Roazzi, M Santaquilani, A Tavilla, F Valente, A Verdecchia (Istituto Superiore di Sanità, Rome); Malta: M Dalmas (Malta National Cancer Registry); Norway: F Langmark, A Andersen (Cancer Registry of Norway, Institute of Population-based Cancer Research); Poland: J Rachtan (Cracow Cancer Registry), M Bielska–Lasota, Z Wronkowski (Warsaw Cancer Registry); Slovakia: I Pleško, A Obsitníková (National Cancer Registry of Slovakia); Slovenia: V Pompe–Kirn, Maja Primic Žakelj (Cancer Registry of Slovenia); Spain: I Izarzugaza (Basque Country Cancer Registry), C Martinez-Garcia (Granada Cancer Registry), I Garau (Mallorca Cancer Registry), C Navarro, MD Chirlaque (Murcia Cancer Registry), E Ardanaz, C Moreno (Navarra Cancer Registry), J Galceran (Tarragona Cancer Registry), A Torrella (Childhood Tumor Registry of Valencia), R Peris-Bonet (National Childhood Cancer Registry and Instituto Lopez Pinero, Valencia); Sweden: L Barlow, T Möller (Cancer Registry of Sweden); Switzerland: G Jundt (Basel Cancer Registry), JM Lutz, C Bouchardy (Geneva Cancer Registry); The Netherlands: JWW Coebergh (Eindhoven Cancer Registry), O Visser (Amsterdam Cancer Registry); UK - England: S Godward (East Anglian Cancer Registry), MP Coleman (London School of Hygiene and Tropical Medicine), EMI Williams (Merseyside and Cheshire Cancer Registry), D Forman (Northern and Yorkshire Cancer Registry and Information Service), MJ Quinn (Office for National Statistics), M Roche, S Edwards (Oxford Cancer Intelligence Unit), C Stiller (Childhood Cancer Research Group, Oxford), J Verne (South West Cancer Intelligence Services), H Møller, J Bell (Thames Cancer Registry), JL Botha, (Trent Cancer Registry), G Lawrence (West Midlands Cancer Intelligence Unit); UK - Scotland: R Black (Scottish Cancer Intelligence Unit); UK - Wales: JA Steward (Welsh Cancer Intelligence and Surveillance Unit).
ABSTRACT